Remed Co (XKRX:302550) Debt-to-Equity : 0.54 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Remed Co Debt-to-Equity?

Remed Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩14,358 Mil. Remed Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩2,329 Mil. Remed Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩30,826 Mil. Remed Co's debt to equity for the quarter that ended in Dec. 2023 was 0.54.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Remed Co's Debt-to-Equity or its related term are showing as below:

XKRX:302550' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.27 Med: 0.65 Max: 0.94
Current: 0.54

During the past 7 years, the highest Debt-to-Equity Ratio of Remed Co was 0.94. The lowest was 0.27. And the median was 0.65.

XKRX:302550's Debt-to-Equity is ranked worse than
74.96% of 711 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs XKRX:302550: 0.54

Remed Co Debt-to-Equity Historical Data

The historical data trend for Remed Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remed Co Debt-to-Equity Chart

Remed Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.27

0.77

0.75

0.65

0.54

Remed Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.65	0.64	0.67	0.44	0.54

Competitive Comparison of Remed Co's Debt-to-Equity

For the Medical Devices subindustry, Remed Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Remed Co's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Remed Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Remed Co's Debt-to-Equity falls into.

Remed Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Remed Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(14358.291	+	2329.022)	/	30826.041
	=	0.54

Remed Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(14358.291	+	2329.022)	/	30826.041
	=	0.54

Remed Co (XKRX:302550) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Remed Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Remed Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Remed Co (XKRX:302550) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remed Co Ltd (XKRX:302550) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

187 Techno 2-ro, No 301-303, Gwanpyeong-dong, Yuseong-gu, Daejeon, KOR, 34025

Website

http://www.remed.kr

Remed Co Ltd is a Korean medical equipment manufacturing company. The company is engaged in researching and developing products to treat brain disorders such as depression, anxiety, stroke and Parkin's. It has developed TMS device and is manufacturing pain therapy devices using advanced electromagnetic stimulation, shockwave (RSWT) and laser technologies. Its products offerings include Transcranial Magnetic simulator for brain, Electromagnetic simulators including Salus Talent, Salus Talent A, Salus Talent Pro, and Optimus Pro for pain therapy; and Rosetta, Salus RSWT and Optimus Pro as a part of Extracorporeal Shockwave Therapy. It also offers Electrosurgical units from REMED including ELPIS 4L, ELPIS 4, ELPIS 3, and ELPIS2.

Remed Co (XKRX:302550) Headlines

No Headlines